Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
2010; American Diabetes Association; Volume: 33; Issue: 7 Linguagem: Inglês
10.2337/dc09-2009
ISSN1935-5548
AutoresJ. Michael Gaziano, Anthony H. Cincotta, Christopher M. O’Connor, Michael Ezrokhi, Dean Rutty, Zhulin Ma, Richard E. Scranton,
Tópico(s)Pancreatic function and diabetes
ResumoQuick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy for type 2 diabetes.
Referência(s)